AVBP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $17,999,982.00
Insider Selling (Last 12 Months): $0.00

ArriVent BioPharma Insider Trading History Chart

This chart shows the insider buying and selling history at ArriVent BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ArriVent BioPharma Share Price & Price History

Current Price: $18.77
Price Change: Price Decrease of -0.43 (-2.24%)
As of 07/19/2024 01:00 AM ET

This chart shows the closing price history over time for AVBP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

ArriVent BioPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2024Hillhouse Investment ManagemenMajor ShareholderBuy555,555$18.00$9,999,990.004,484,672View SEC Filing Icon  
1/30/2024Orbimed Advisors LlcDirectorBuy444,444$18.00$7,999,992.001,513,664View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for ArriVent BioPharma (NASDAQ:AVBP)

9.48% of ArriVent BioPharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVBP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

ArriVent BioPharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/24/2024Farallon Capital Management LLC151,768$2.71M0.0%N/A0.453%Search for SEC Filing on Google Icon
5/16/2024Blackstone Inc.25,000$0.45M0.0%N/A0.075%Search for SEC Filing on Google Icon
5/15/2024Hhlr Advisors LTD.3,929,117$70.17M1.5%N/A11.732%Search for SEC Filing on Google Icon
5/15/2024Altitude Crest Partners Inc.555,555$9.92M4.2%N/A1.659%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.4,845$87K0.0%N/A0.014%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.648,735$11.59M0.0%N/A1.937%Search for SEC Filing on Google Icon
5/1/2024BNP Paribas Financial Markets4,659$83K0.0%N/A0.014%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
ArriVent BioPharma logo
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Read More on ArriVent BioPharma

Today's Range

Now: $18.77
Low: $18.39
High: $19.70

50 Day Range

MA: $18.66
Low: $16.60
High: $20.15

52 Week Range

Now: $18.77
Low: $14.35
High: $25.95

Volume

36,012 shs

Average Volume

73,208 shs

Market Capitalization

$628.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ArriVent BioPharma?

ArriVent BioPharma's top insider investors include:
  1. Hillhouse Investment Managemen (Major Shareholder)
  2. Orbimed Advisors Llc (Director)
Learn More about top insider investors at ArriVent BioPharma.